Last week Numinus (TSXV:NUMI, OTC:LKYSF) closed a C$40 million bought deal.
Numinus now has $65-million on hand and is well capitalized to act on revenue-generating growth initiatives including the Numinus Bioscience lab expansion, clinic acquisitions, and purpose-built flagship facilities.
Armed with a war chest of cash ahead of its clinical trials, this company could be making some serious moves in the near future.
With the virus still affecting across the globe, new strains emerging, and lockdowns still in place, life sciences company Numinus (TSXV:NUMI, OTC:LKYSF) is easily among the most consequential plays we have ever profiled.
If this is the first time you're hearing about Numinus and their remarkable potential, read our report right here...